Gui Yu, Xu Shuman, Yang Xi, Gu Lu, Zhang Ze, Luo Xiangdong, Chen Li
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Burn Research Institute, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Biomark Med. 2016 Jul;10(7):771-90. doi: 10.2217/bmm-2015-0064. Epub 2016 Jun 24.
Identification of biomarkers that has the ability to predict triple-negative breast cancer (TNBC) prognosis especially in patients undergoing chemotherapy is very important.
The cohort studies that reported association between chemotherapy biomarker expression and survival outcome in TNBC patients were included in our analysis.
The promising markers that emerged for the prediction of disease-free survival and overall survival included Ki67, BRCA1 methylation and LC3B. Furthermore, Ki67 appeared to be also significantly associated with worse disease-free survival in TNBC patients who received anthracycline-based chemotherapy.
This meta-analysis demonstrated that in TNBC patients receiving chemotherapy, Ki67 is a predictor for poor prognosis, BRCA1 methylation and LC3B are also potential prognostic markers. In addition, the TNBC patients with high Ki67 expression seems to display resistance to anthracycline-based chemotherapy.
识别能够预测三阴性乳腺癌（TNBC）预后的生物标志物非常重要，尤其是对于接受化疗的患者。
我们的分析纳入了报告化疗生物标志物表达与TNBC患者生存结果之间关联的队列研究。
在预测无病生存期和总生存期方面出现的有前景的标志物包括Ki67、BRCA1甲基化和LC3B。此外，在接受蒽环类化疗的TNBC患者中，Ki67似乎也与较差的无病生存期显著相关。
这项荟萃分析表明，在接受化疗的TNBC患者中，Ki67是预后不良的预测指标，BRCA1甲基化和LC3B也是潜在的预后标志物。此外，Ki67表达高的TNBC患者似乎对蒽环类化疗表现出耐药性。
